Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.

BACKGROUND The polycystic ovary syndrome is a common cause of infertility. Clomiphene and insulin sensitizers are used alone and in combination to induce ovulation, but it is unknown whether one approach is superior. METHODS We randomly assigned 626 infertile women with the polycystic ovary syndrome to receive clomiphene citrate plus placebo, extended-release metformin plus placebo, or a combination of metformin and clomiphene for up to 6 months. Medication was discontinued when pregnancy was confirmed, and subjects were followed until delivery. RESULTS The live-birth rate was 22.5% (47 of 209 subjects) in the clomiphene group, 7.2% (15 of 208) in the metformin group, and 26.8% (56 of 209) in the combination-therapy group (P<0.001 for metformin vs. both clomiphene and combination therapy; P=0.31 for clomiphene vs. combination therapy). Among pregnancies, the rate of multiple pregnancy was 6.0% in the clomiphene group, 0% in the metformin group, and 3.1% in the combination-therapy group. The rates of first-trimester pregnancy loss did not differ significantly among the groups. However, the conception rate among subjects who ovulated was significantly lower in the metformin group (21.7%) than in either the clomiphene group (39.5%, P=0.002) or the combination-therapy group (46.0%, P<0.001). With the exception of pregnancy complications, adverse-event rates were similar in all groups, though gastrointestinal side effects were more frequent, and vasomotor and ovulatory symptoms less frequent, in the metformin group than in the clomiphene group. CONCLUSIONS Clomiphene is superior to metformin in achieving live birth in infertile women with the polycystic ovary syndrome, although multiple birth is a complication. (ClinicalTrials.gov number, NCT00068861 [ClinicalTrials.gov].).

[1]  D. Jakubowicz,et al.  Effects of metformin on early pregnancy loss in the polycystic ovary syndrome , 2002, The Journal of clinical endocrinology and metabolism.

[2]  P. Bossuyt,et al.  Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial , 2006, BMJ : British Medical Journal.

[3]  D. Jakubowicz,et al.  Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. , 1998, The New England journal of medicine.

[4]  R. Norman,et al.  Should we continue or stop insulin sensitizing drugs during pregnancy? , 2004, Current opinion in obstetrics & gynecology.

[5]  F. Keleştimur,et al.  The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. , 2004, European journal of obstetrics, gynecology, and reproductive biology.

[6]  F. Naftolin,et al.  Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. , 1976, The Journal of clinical investigation.

[7]  M. Cedergren.  Maternal Morbid Obesity and the Risk of Adverse Pregnancy Outcome , 2004, Obstetrics and gynecology.

[8]  F. Manguso,et al.  Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[9]  H. Barnhart,et al.  The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. , 2006, Fertility and sterility.

[10]  Maternal Morbid Obesity and the Risk of Adverse Pregnancy Outcome , 2004 .

[11]  N. Johnson.  No more surrogate end‐points in randomised trials: The PCOSMIC trial protocol for women with polycystic ovary syndrome using metformin for infertility with clomiphene , 2006, The Australian & New Zealand journal of obstetrics & gynaecology.

[12]  ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. , 2002, Obstetrics and gynecology.

[13]  W. Evans,et al.  Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. , 2001, Fertility and sterility.

[14]  Ricardo Azziz,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6):2745–2749 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-032046 The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected , 2022 .

[15]  G. Levy,et al.  Pharmacokinetics of Metformin Gastric‐Retentive Tablets in Healthy Volunteers , 2001, Journal of clinical pharmacology.

[16]  L. Bisanti,et al.  Body mass index and delayed conception: a European Multicenter Study on Infertility and Subfecundity. , 2000, American journal of epidemiology.

[17]  T. Ozaki,et al.  Transvaginal ultrasonic assessment of the response to clomiphene citrate in polycystic ovarian syndrome. , 1994, Fertility and sterility.

[18]  Dolian Gg,et al.  Diagnostic criteria for polycystic ovary syndrome , 1989 .

[19]  V. Fonseca,et al.  Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. , 2006, Diabetes care.

[20]  Mary E D'Alton,et al.  Obesity, obstetric complications and cesarean delivery rate--a population-based screening study. , 2004, American journal of obstetrics and gynecology.

[21]  D. Jakubowicz,et al.  Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. , 1999, The New England journal of medicine.

[22]  J. Adams,et al.  Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. , 1988, BMJ.

[23]  E. Çalışkan,et al.  Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. , 2002, Fertility and sterility.

[24]  M. Eijkemans,et al.  A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. , 2006, Human reproduction update.

[25]  R. Norman,et al.  Metformin in polycystic ovary syndrome: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[26]  K. Segal,et al.  Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome , 1989, Diabetes.

[27]  E. Myers,et al.  Estimating live birth rates after ovulation induction in polycystic ovary syndrome: sample size calculations for the pregnancy in polycystic ovary syndrome trial. , 2005, Contemporary clinical trials.

[28]  D. Ehrmann,et al.  Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. , 2001, The Journal of clinical endocrinology and metabolism.

[29]  P. Claman.  Men at risk: occupation and male infertility. , 2004, Fertility and sterility.

[30]  L. Giudice,et al.  Utility of screening for other causes of infertility in women with "known" polycystic ovary syndrome. , 2007, Fertility and sterility.

[31]  K. Fujioka,et al.  Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studies , 2005, Diabetes, obesity & metabolism.

[32]  M. Hull.  Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. , 1987, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[33]  L. Nardo,et al.  Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. , 2004, The Journal of clinical endocrinology and metabolism.

[34]  I. Stein,et al.  Amenorrhea associated with bilateral polycystic ovaries , 1935 .

[35]  E. Myers,et al.  Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome? , 2004, Human reproduction.